MONTREAL, Oct. 06, 2017 -- I-MED Pharma, Inc., a Canadian company specialized in dry eye diagnosis and management, announced today the appointment of AMWO Farma IVS as its exclusive distributor for the I-PEN® Tear Osmolarity System as well as the I-DROP® and I-LID ‘N LASH® dry eye products in Denmark, Sweden and Norway.
|
|||||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a0c0fde2-b539-4851-adf7-8ed42648e5fb
Daniel Hofmann, President of I-MED commented, “We are pleased to have the opportunity to introduce our innovative products to Scandinavian eye care professionals and to give them new options for rapid, reliable diagnosis and effective, long lasting symptom relief for their dry patients.”
AMWO Farma CEO Claus Oldenburg said, “We are excited about our new relationship with I-MED Pharma and we look forward to introducing the I-PEN®, as well the Ocular Surface Disorder (OSD) line of products to ophthalmologists, optometrists and their patients. I-MED Pharma’s unique products offer a major leap forward in our efforts to improve the vision and quality of life of people with dry eye problems.”
I-MED Pharma is a privately held Canadian company, headquartered in Montreal, Quebec, servicing Canadian ophthalmologists, optometrists and the global eye care community. Established over twenty-five years ago, I-MED Pharma Inc. creates and distributes innovative medical, surgical and veterinary eye care products. It continually researches, develops and sources the most effective and advanced solutions to eye disorders like cataracts, corneal degenerations, dry eye, glaucoma and Meibomian gland disease.
I-MED Pharma is proud to have been at the forefront of treating Dry Eye Syndrome as a serious disease and investing heavily into education and developing effective dry eye products. Most recently, I-MED Pharma launched the world’s first hand-held in-vivo tear osmolarity test, the I-PEN® osmolarity device. I-MED Pharma’s ocular surface disease product range includes diagnostic tools, ocular hygiene, nutrition, dry eye drops and ocular occlusion devices.
For more information please email [email protected] or visit www.imedpharma.com.


Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Chinese Cars in Europe: Consumer Trust Is Shifting Fast
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
Bill Ackman Eyes New Fund to Bet Against Market Complacency
OpenAI Addresses Security Vulnerability in macOS App Certification Process
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 



